Pathogenesis of Natural SIV and STLV Infections in Humans

人类自然 SIV 和 STLV 感染的发病机制

基本信息

  • 批准号:
    8318794
  • 负责人:
  • 金额:
    $ 65.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-25 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall objective of this project is to assess the risk of emergence of new HIV types from SIV-infected persons in Cameroon. This objective will be obtained by using a new strategy for testing for persons naturally infected with SIV, characterizing their infections and testing for infection in their contacts. Both sexual and causal contacts will be studied. The feasibility of such a project was recently established in preliminary studies using SIV assays in Anglophone Cameroon. We tested 1536 persons attending clinics in and near Kumba, Cameroon for any reason, mostly fevers and other acute illnesses. We used western blots followed by SIV-specific SIV peptide ELISA on all positive and indeterminants results. This new approach identified 6 persons with SIV antibody, 1 SIVcpz, 1 SIVagm and 2 each for SIVrcm and SIVmnd. Aim 1. To screen the general human population in Southwest Cameroon for SIV infections. We will use antibody assays that have already been validated in this region. We will also employ PCR-based testing. Aim 2. To characterize the virologic and phylogenetic properties of SIV either isolated or amplified from humans in Cameroon. For example, we will test G->A hypermutation for testing for adaptation of SIV to humans. Aim 3. To characterize the epidemiology and natural history of SIV infections in humans exposed to simian viruses. We will examine replication, transmission and pathogenesis. Contacts will be tested to determine if these retroviruses are transmissible between humans. The outcome of these infections in humans will be addressed. SIV antibody + persons will have repeated clinical follow-ups. Thus far, SIV-like infections in humans have been dead end infections. This approach will enable us to find and track SIV human infections to assess the risk for emergence of new HIVs. Other groups both French and American are working in Cameroon, but the relatively low sero-prevalence for these viruses warrants other groups being funded to increase the chances of finding active SIV infections in the acute stage. PUBLIC HEALTH RELEVANCE: The root causes for the emergence of the AIDS viruses remain unknown even though this knowledge is vital to prevent the emergence of new epidemics. Although simian immunodeficiency viruses (SIVs) in Africa have been identified as the original source of the AIDS viruses, nothing is known as to why 2 different SIVs suddenly emerged to become epidemic human AIDS viruses in the 20th century. This project will trace the natural history SIV infections in humans to understand how the AIDS epidemic began.
描述(由申请人提供):该项目的总体目标是评估喀麦隆SIV感染者出现新的HIV类型的风险。这一目标将通过采用一种新的战略来实现,即对自然感染SIV的人进行检测,确定其感染特征,并检测其接触者的感染情况。将研究性接触和因果接触。最近,在讲英语的喀麦隆,利用SIV检测法进行的初步研究确定了这一项目的可行性。我们测试了1536人在昆巴和附近的诊所,喀麦隆的任何原因,主要是发烧和其他急性疾病。我们对所有阳性和不确定性结果使用蛋白质印迹法,然后使用SIV特异性SIV肽ELISA。这种新的方法鉴定出6人具有SIV抗体,1人具有SIVcpz,1人具有SIVagm,2人具有SIVrcm和SIVmnd。目标1.在喀麦隆西南部的一般人群中筛查SIV感染。我们将使用已在该地区验证的抗体检测。我们还将采用基于PCR的测试。目标2.描述从喀麦隆人类分离或扩增的SIV的病毒学和系统发育特性。例如,我们将测试G->A超突变以测试SIV对人类的适应性。目标3。描述暴露于猴病毒的人类SIV感染的流行病学和自然史。我们将研究复制,传播和发病机制。将对接触者进行检测,以确定这些逆转录病毒是否可在人类之间传播。将讨论这些感染在人类中的结果。SIV抗体阳性者将重复进行临床随访。到目前为止,人类的SIV样感染一直是死胡同感染。这种方法将使我们能够发现和跟踪SIV人类感染,以评估新的HIV出现的风险。法国和美国的其他小组正在喀麦隆工作,但这些病毒的血清流行率相对较低,因此需要资助其他小组,以增加发现急性期活动性SIV感染的机会。公共卫生相关性:艾滋病病毒出现的根本原因仍然不明,尽管这一知识对于防止新的流行病的出现至关重要。虽然非洲的猿免疫缺陷病毒(SIV)已被确定为艾滋病病毒的原始来源,但对于为什么两种不同的SIV突然出现并成为世纪流行的人类艾滋病病毒却一无所知。该项目将追踪人类SIV感染的自然史,以了解艾滋病流行是如何开始的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Preston A Marx其他文献

Frag-Virus: a new term to distinguish presumptive viruses known primarily from sequence data
  • DOI:
    10.1186/1743-422x-5-34
  • 发表时间:
    2008-02-27
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Alexander Voevodin;Preston A Marx
  • 通讯作者:
    Preston A Marx
Prevalence of HIV-2 and ART treatment coverage in Northern Sierra Leone
  • DOI:
    10.1186/1471-2334-14-s2-p15
  • 发表时间:
    2014-05-23
  • 期刊:
  • 影响因子:
    3.000
  • 作者:
    Nell G Bond;Augustine Goba;Danielle Levy;Lina M Moses;Sallieu K Sesay;Idriss Bangura;Matthew Kemoh Gibateh;Sheik H Khan;Preston A Marx
  • 通讯作者:
    Preston A Marx
Serial passage of HIV-2F: a pigtail macaque model for HIV emergence
  • DOI:
    10.1186/1471-2334-14-s2-p57
  • 发表时间:
    2014-05-23
  • 期刊:
  • 影响因子:
    3.000
  • 作者:
    Nell G Bond;Stephanie L Feely;Christopher Monjure;Michael Lauck;David O’Connor;Nick Manness;Preston A Marx
  • 通讯作者:
    Preston A Marx

Preston A Marx的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Preston A Marx', 18)}}的其他基金

VIRUS CHALLENGE STOCK PRODUCTION AND STORAGE
病毒挑战库存的生产和储存
  • 批准号:
    8358057
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY
用于诱导粘膜免疫的 DNA 疫苗
  • 批准号:
    8358091
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
HIGHLY EFFECTIVE CONTROL OF AIDS VIRUS CHALLENGE IN MACAQUES
高效控制猕猴中的艾滋病病毒挑战
  • 批准号:
    8358058
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
EFFICACY AND TOXICITY OF CSIC AND RETROCYCLIN IN THE SIV VAGINAL CHALLENGE MODEL
CSIC 和逆环素在 SIV 阴道挑战模型中的功效和毒性
  • 批准号:
    8358131
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
Primate Studies
灵长类动物研究
  • 批准号:
    8720871
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
PATHOGENESIS OF NATURAL SIV AND STLV INFECTIONS IN HUMANS
人类自然 SIV 和 STLV 感染的发病机制
  • 批准号:
    8358130
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
ISOLATION OF A NEW HIV-2 GROUP IN THE US
美国隔离新的 HIV-2 群体
  • 批准号:
    8358116
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
NHP PILOT STUDY OF A NOVEL PROTEIN ADJUVANT FOR VACCINES AGAINST HUMAN PATHOGENS
NHP 针对人类病原体疫苗的新型蛋白质佐剂的试点研究
  • 批准号:
    8358134
  • 财政年份:
    2011
  • 资助金额:
    $ 65.66万
  • 项目类别:
HIV ENV EPITOPE ENGINEERING
HIV环境表位工程
  • 批准号:
    8173047
  • 财政年份:
    2010
  • 资助金额:
    $ 65.66万
  • 项目类别:
DNA VACCINE FOR INDUCTION OF MUCOSAL IMMUNITY
用于诱导粘膜免疫的 DNA 疫苗
  • 批准号:
    8172993
  • 财政年份:
    2010
  • 资助金额:
    $ 65.66万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 65.66万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了